Your browser doesn't support javascript.
loading
Pertuzumab Plus Trastuzumab for Treatment-Refractory HER2-Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm.
Narita, Yusuke; Yoshimoto, Takuya; Namai, Tomoyuki; Asakawa, Takashi; Kawakami, Satoe; Gower-Page, Craig; Reyes-Rivera, Irmarie; Patel, Arisha; Nakamura, Yoshiaki.
Affiliation
  • Narita Y; Chugai Pharmaceutical Co, Ltd, Tokyo, Japan.
  • Yoshimoto T; Chugai Pharmaceutical Co, Ltd, Tokyo, Japan.
  • Namai T; Chugai Pharmaceutical Co, Ltd, Tokyo, Japan.
  • Asakawa T; Chugai Pharmaceutical Co, Ltd, Tokyo, Japan.
  • Kawakami S; Chugai Pharmaceutical Co, Ltd, Tokyo, Japan.
  • Gower-Page C; Roche Products Ltd, Welwyn, Garden City, United Kingdom.
  • Reyes-Rivera I; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Patel A; Genentech Inc, South San Francisco, CA.
  • Nakamura Y; National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
JCO Clin Cancer Inform ; 6: e2200022, 2022 05.
Article in En | MEDLINE | ID: mdl-35649212
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Colonic Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: JCO Clin Cancer Inform Year: 2022 Document type: Article Affiliation country: Japan Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Colonic Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: JCO Clin Cancer Inform Year: 2022 Document type: Article Affiliation country: Japan Country of publication: United States